EnginZyme
EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes.
SEK 75MEquity round
ParticipantSP
Sofinnova Partners
Activity from announced rounds
Activity in this selectionBiotech
- Rounds participated in
- 8
- Confirmed lead rounds
- 0 6 roles undisclosed
- New companies
- 8 First participation on record · 0 follow-on
- Funding in participating rounds
- $724.7M 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
8 in this selectionMironid
Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease.
$46MSeries B
ParticipantBionyra Pharma
Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases.
$165MSeries A
Role not disclosedIngenix
Builds AI architecture fusing biological data modalities to accelerate pharma and biotech drug development
€13MSeed+
Role not disclosedP2 Science
Designs and manufactures renewable specialty ingredients for personal care, fragrance, and performance materials
$23MUndisclosed
Role not disclosedCellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedSignadori Bio
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
€11.1MSeed+
Role not disclosedTenpoint Therapeutics
Develops treatments to rejuvenate vision in the aging eye
$235MSeries B
Role not disclosed